Hyperglycemia is a key therapeutic focus in the management of patients with type 2 diabetes (T2D) mellitus. The various therapeutic classes of antidiabetic drugs presently existing in the market are not sufficiently effective in maintaining long-term glycemic control in most of the diabetic patients, even when used in combination. The undesirable adverse effects of these drugs, such as hypoglycemia, weight gain, and hepatic and renal toxicity, have escalated the demand for the discovery of new and safer antidiabetic drugs. The progressive nature of T2D requires practitioners to periodically evaluate patients and intensify glucose-lowering treatment once glycemic targets are not attained. Sodium-glucose cotransporter 2 inhibitors (SGLT2-is) are the new class of antidiabetic medications that are approved (2013) by the Food and Drug Administration recently for treating diabetes. These inhibitors block the SGLT2 protein involved in glucose reabsorption from the proximal renal tubule resulting in escalated glucose excretion and lower blood glucose levels. These inhibitors exhibit favorable effects beyond glucose control, such as consistent body weight, blood pressure, and serum uric acid reductions. This review highlighted the brief updates of SGLT2-i, their benefits, and adverse effects.

Keywords: Type-2 diabetes mellitus, Sodium-glucose linked cotransporter 2, Sodium-glucose linked cotransporter 2 inhibitors, Gliflozins, Antidiabetic drugs

Author Biography

REKHA BISHT, Department of Pharmacology, Indore Institute of Pharmacy, Indore, Madhya Pradesh, India.

Indore Institute of Pharmacy, Indore (M.P.)

Assistant Professor


1. Mosley JF, Smith L, Everton E, Fellner C. Sodium-glucose linked transporter 2 (SGLT 2) inhibitors in the management of Type-2 diabetes: A drug class overview. P T 2015;40:451-62.
2. Doroshkevych I, Vozniuk L, Klekot A. Efficiency and safety of SGLT 2 inhibitors. Diabetes Metab 2016;42:299.
3. Madaan T, Akhtar M, Kalam NA. Sodium glucose co-transporter 2 (SGLT 2) inhibitors: Current status and future perspective. Eur J Pharm Sci 2016;93:244-52.
4. Levine MJ. Empagliflozin for Type 2 diabetes mellitus: An overview of phase 3 clinical trials. Curr Diabetes Rev 2017;13:405-23.
5. Hsia DS, Owen G, Cefalu WT. An update on SGLT2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2017;24:73-9.
6. Van Baar MJ, Van Ruiten CC, Muskiet MH, Bloemendaal LV, IJzerman RG, van Raalte DH. SGLT2 inhibitors in combination therapy: From mechanisms to clinical considerations in Type 2 diabetes management. Diabetes Care 2018;41:1543-56.
7. Bays H. Sodium-glucose co-transporter Type 2 (SGLT2) inhibitors: Targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther 2013;4:195-220.
8. Choi C. Sodium-glucose co-transporter 2 (SGLT2) inhibitors from natural products: Discovery of next-generation anti-hyperglycemic agents. Molecules 2016;21:1136.
9. Yang Y, Chen S, Pan H, Zou Y, Wang B, Wang G, et al. Safety and efficiency of SGLT2 inhibitor combining with insulin in subjects with diabetes systematic review and meta-analysis of randomized controlled trials. Medicine 2017;96:21.
10. Kalra S. Sodium-glucose co-transporter-2 (SGLT 2) inhibitors: A review of their basic and clinical pharmacology. Diabetes Ther 2014;5:355-66.
11. Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia 2018;61:2079-86.
12. Chawla G, Chaudhary KK. A complete review of empagliflozin: Most specific and potent SGLT 2 inhibitor used for the treatment of Type 2 diabetes mellitus. Res Rev 2019;13:2001-8.
13. Kathleen A, Lusk NE. Barnes role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors. US Pharm 2016;41:26-9.
14. Anastasios T, Panayotis V, Evangelia T, Ioanna E, Nikolaos T. SGLT2 Inhibitors: A review of their antidiabetic and cardio-protective effects. Int J Environ Res Public Health 2019;16:2965.
15. Masayuki I. SGLT2 inhibitors: Molecular design and potential differences in effect. Kidney Int 2011;79:S14-9.
16. Fattah H, Vallon V. The potential role of SGLT 2 inhibitors in the treatment of Type 1 diabetes mellitus. Drugs 2018;78:717-26.
17. Kaushal S, Singh H, Thangaraju P, Singh J. Canagliflozin: A novel SGLT 2 inhibitor for Type 2 diabetes mellitus. N Am J Med Sci 2014;6:107-13.
18. Akil H, Rokeya P. Current antidiabetic drugs: Review of their efficacy and safety. In: Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome. 2nd ed. Amsterdam, Netherlands: Elsevier; 2018. p. 455-73.
19. Simes BC, MacGregor GG. Sodium-glucose cotransporter-2 (SGLT2) inhibitors: A clinician’s guide. Diabetes Metab Syndr Obes 2019;12:2125-36.
20. Wilding J, Fernando K, Milne N, Evans M, Ali A, Bain S, et al. SGLT2 inhibitors in Type 2 diabetes management: Key evidence and implications for clinical practice. Diabetes Ther 2018;9:1757-73.
21. David LJ. SGLT2 Inhibitors: A New Class of Diabetes Medications. Diabetes in Control: News and Information for Medical Professionals; 2018. Available from: inhibitors-a-new-class-of-diabetes-medications.
22. Beatrice CL, Silvio EI. Use of SGLT2 inhibitors in Type 2 diabetes: Weighing the risks and benefits. Diabetologia 2018;61:2118-25.
23. Rico-Fontalvo J, Daza-Arnedo R, Cardona-Blanco MX, Leal-Martínez V, Abuabara E, Pajaro-Galvis N, et al. SGLT2 inhibitors and nephron-protection in diabetic kidney disease: From mechanisms of action to the latest evidence in the literature. J Clini Nephrol 2020;4:44-55.
24. Maria JP, Jan WE. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs 2019;79:219-30.
25. Wanner C, Marx N. SGLT2 inhibitors: The future for treatment of Type 2 diabetes mellitus and other chronic diseases. Diabetologia 2018;61:2134-9.
26. Mouhayyar CE, Riachy R, Khalil AB, Eid A, Azar S. SGLT2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors in diabetes and microvascular complications: A review. Int J Endocrinol 2020;2020:1762164.
27. Hou YC, Zheng CM, Yen TH, Lu KC. Molecular mechanisms of SGLT2 inhibitor on cardiorenal protection. Int J Mol Sci 2020;21:7833.
28. Jiwen L, Tae WL. SGLT2 inhibitors for Type 2 diabetes. Annu Rep Med Chem 2011;46:103-15.
29. Gary DL, Subodh V. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review. JACC Basic Transl Sci 2020;5:632-44.
30. Marshall SM. Thebark giving diabetes therapy some bite: The SGLT inhibitors. Diabetologia 2018;61:2075-8.
31. William T, Cefalu MC Riddle. SGLT2 inhibitors: The latest “new kids on the block”! Diabetes Care 2015;38:352-4.
32. Lo KB, Gul F, Ram P, Kluger AY, Tecson KM, McCullough PA. Rangaswami J. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: A systematic review and meta-analysis. Cardiorenal Med 2020;10:1-10.
33. Beatriz FF, Pantelis S, Mehmet K, Juan FN, María JS, Jose LG, et al. SGLT2inhibitors for non-diabetic kidney disease: Drugs to treat CKD that also improve glycaemia. Clin Kidney J 2020;13:728-33.
34. Reed JW. Impact of sodium-glucose co-transporter-2 inhibitors on blood pressure. Vasc Health Risk Manag 2016;12:393-405.
35. Carolyn SP, Chanchal C, Vineeta A, Subodh V. SGLT-2 inhibitors in heart failure: Current management, unmet needs, and therapeutic prospects. J Am Heart Assoc 2019;8:20.
36. Matthew HK, Joseph K, Niklas HE. Drug use of dapagliflozin prescribed by general practitioners and diabetologists in Germany. Diabetes Res Clin Pract 2017;125:29-38.
37. Li F, Gao G, Zhu H, Su X, Wu J, Ye L, et al. Influence of dapagliflozin on glycemic variation in patients with newly diagnosed Type 2 diabetes mellitus. J Diabetes Res 2016;2016:5347262.
38. National Library of Medicine. Dapagliflozin Propanediol. Bethesda, Maryland: National Library Medicine; 2020.
39. Eva MV. Dapagliflozin: A new sodium-glucose cotransporter-2 inhibitor for treatment of Type 2 diabetes. Am J Health Syst Pharm 2015;72:361-72.
40. Greg LP. Dapagliflozin: A review of its use in Type 2 diabetes mellitus. Drugs 2012;72:2289-312.
41. Miao F, Lv H, Xu X, Wang J, Lyu W, Fu S. Efficacy and safety of dapagliflozin as monotherapy in patients with Type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019;98:30.
42. Han S, Hagan DL, Taylor JR, Xin L, Meng W, Biller SA, et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008;57:1723-9.
43. Sun Y, ZhouY, Chen X, Che W, Leung S. The efficacy of dapagliflozin combined with hypoglycemic drugs in treating Type 2 diabetes Protocol for meta-analysis of randomized controlled trials. Syst Rev 2013;2:103.
44. Dhillon S. Dapagliflozin: A review in Type 2 diabetes. Drugs 2019;79:1135-46.
45. Wei X, Yue XM, Mei Z, Fei C. Efficacy and safety of canagliflozin in patients with Type 2 diabetes: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016;95:e5473.
46. Meininger G, Canovatchel W, Polidori D, Rosenthal N. Canagliflozin for the treatment of adults with Type 2 diabetes. Diabetes Manag 2015;5:183-201.
47. Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with Type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82.
48. Roberts TM, Johnson JF, Vaughan AG. Canagliflozin in Type 1 diabetes: A case series of patient outcomes in a diabetes clinic. Diabetes Spectr 2019;32:47-51.
49. Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: Cohort study. Br Med J 2020;370:m2812.
50. Caffrey M. CREDENCE: First renal outcomes trial finds canagliflozin cuts risk of renal failure, death; prompts ADA updates. Am J Manag Care 2019;25:SP230-2.
51. Frampton JE. Empagliflozin: A review in Type 2 diabetes. Drugs 2018;78:1037-48.
52. Ertugliflozin for Type 2 diabetes. JAMA 2018;319:2434-5.
53. Sharma V, Sharma S, Jaiswal S, Ghanghas RR, Boddepalli D, Sharma AK. Ertugliflozin: A novel anti-diabetic drug. Int J Basic Clin Pharmacol 2018;7:2472-5.
54. Nguyen VK, White JR Jr. Overview of ertugliflozin. Clin Diabetes 2019;37:176-8.
55. National Library of Medicine. Nicotine. Bethesda, Maryland: National Library of Medicine; 2020.
37 Views | 63 Downloads
How to Cite
BISHT, R. “SODIUM-GLUCOSE LINKED COTRANSPORTER 2 INHIBITOR: A NEW HORIZON IN THE TREATMENT OF TYPE-2 DIABETES”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 3, Mar. 2021, pp. 45-48, doi:10.22159/ajpcr.2021.v14i3.39667.
Review Article(s)